Form 4: Telomir Pharmaceuticals Director Acquires Incentive Stock Options

Matthew Paul Del Giudice, a director of Telomir Pharmaceuticals, acquired incentive stock options for 25,000 shares on August 27, 2024.

Summary

• On August 27, 2024, Matthew Paul Del Giudice, a director of Telomir Pharmaceuticals, acquired incentive stock options.
• These options grant him the right to buy 25,000 shares of Telomir Pharmaceuticals common stock at an exercise price of $5.02 per share.
• The options were issued pursuant to the company's 2023 Omnibus Incentive Plan.
• 50% of the options vested immediately, and the remaining 50% will vest on February 26, 2025.
• The options expire on August 27, 2034.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The granting of stock options is generally viewed as a positive sign, aligning management and shareholder interests, but it's a routine event.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
• The vesting schedule encourages the director's continued service with the company.

Industry Context

Stock options are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Granting stock options to directors is a common practice across the pharmaceutical industry.
• The vesting schedule of 50% immediately and 50% after six months is fairly standard.
• The ten-year expiration date is also typical for stock options.

Stakeholder Impact

• Shareholders may view the granting of stock options positively, as it aligns the director's interests with the company's long-term success.
• The director benefits from the potential upside of the stock options.

Key Dates